nodes	percent_of_prediction	percent_of_DWPC	metapath
Linagliptin—ABCB1—Mitoxantrone—lymphatic system cancer	0.169	0.206	CbGbCtD
Linagliptin—CYP3A4—Cytarabine—lymphatic system cancer	0.147	0.18	CbGbCtD
Linagliptin—CYP3A4—Teniposide—lymphatic system cancer	0.144	0.177	CbGbCtD
Linagliptin—ABCB1—Vincristine—lymphatic system cancer	0.116	0.142	CbGbCtD
Linagliptin—CYP3A4—Mitoxantrone—lymphatic system cancer	0.101	0.124	CbGbCtD
Linagliptin—ABCB1—Methotrexate—lymphatic system cancer	0.0702	0.086	CbGbCtD
Linagliptin—CYP3A4—Vincristine—lymphatic system cancer	0.0695	0.0851	CbGbCtD
Linagliptin—Bronchial hyperreactivity—Methotrexate—lymphatic system cancer	0.00701	0.0382	CcSEcCtD
Linagliptin—Diabetic—Methotrexate—lymphatic system cancer	0.00548	0.0298	CcSEcCtD
Linagliptin—Skin exfoliation—Bleomycin—lymphatic system cancer	0.00432	0.0235	CcSEcCtD
Linagliptin—Skin exfoliation—Carmustine—lymphatic system cancer	0.00377	0.0205	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.0036	0.0196	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00352	0.0192	CcSEcCtD
Linagliptin—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0034	0.0185	CcSEcCtD
Linagliptin—Infection—Mechlorethamine—lymphatic system cancer	0.00338	0.0184	CcSEcCtD
Linagliptin—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00336	0.0183	CcSEcCtD
Linagliptin—Skin disorder—Mechlorethamine—lymphatic system cancer	0.0033	0.018	CcSEcCtD
Linagliptin—Diabetes mellitus—Carmustine—lymphatic system cancer	0.0033	0.0179	CcSEcCtD
Linagliptin—Pain in extremity—Vincristine—lymphatic system cancer	0.00274	0.0149	CcSEcCtD
Linagliptin—Malnutrition—Fludarabine—lymphatic system cancer	0.0027	0.0147	CcSEcCtD
Linagliptin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0025	0.0136	CcSEcCtD
Linagliptin—Infection—Teniposide—lymphatic system cancer	0.00249	0.0136	CcSEcCtD
Linagliptin—Cough—Fludarabine—lymphatic system cancer	0.00235	0.0128	CcSEcCtD
Linagliptin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00232	0.0127	CcSEcCtD
Linagliptin—Arthralgia—Fludarabine—lymphatic system cancer	0.0023	0.0125	CcSEcCtD
Linagliptin—Myalgia—Fludarabine—lymphatic system cancer	0.0023	0.0125	CcSEcCtD
Linagliptin—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0022	0.012	CcSEcCtD
Linagliptin—Infection—Fludarabine—lymphatic system cancer	0.00219	0.0119	CcSEcCtD
Linagliptin—Urinary tract infection—Carmustine—lymphatic system cancer	0.00215	0.0117	CcSEcCtD
Linagliptin—Rash—Mechlorethamine—lymphatic system cancer	0.00214	0.0117	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00214	0.0117	CcSEcCtD
Linagliptin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00214	0.0117	CcSEcCtD
Linagliptin—Weight increased—Mitoxantrone—lymphatic system cancer	0.0021	0.0114	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00201	0.0109	CcSEcCtD
Linagliptin—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.002	0.0109	CcSEcCtD
Linagliptin—Urticaria—Teniposide—lymphatic system cancer	0.00199	0.0108	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.0019	0.0103	CcSEcCtD
Linagliptin—Constipation—Fludarabine—lymphatic system cancer	0.00188	0.0103	CcSEcCtD
Linagliptin—Hypersensitivity—Teniposide—lymphatic system cancer	0.00185	0.01	CcSEcCtD
Linagliptin—Skin exfoliation—Methotrexate—lymphatic system cancer	0.00175	0.00951	CcSEcCtD
Linagliptin—Malnutrition—Carmustine—lymphatic system cancer	0.00173	0.0094	CcSEcCtD
Linagliptin—Cough—Bleomycin—lymphatic system cancer	0.00173	0.0094	CcSEcCtD
Linagliptin—Diarrhoea—Teniposide—lymphatic system cancer	0.00171	0.00933	CcSEcCtD
Linagliptin—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00171	0.00929	CcSEcCtD
Linagliptin—Myalgia—Bleomycin—lymphatic system cancer	0.00168	0.00917	CcSEcCtD
Linagliptin—Back pain—Carmustine—lymphatic system cancer	0.00167	0.00909	CcSEcCtD
Linagliptin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00162	0.00883	CcSEcCtD
Linagliptin—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00161	0.00879	CcSEcCtD
Linagliptin—Infection—Bleomycin—lymphatic system cancer	0.0016	0.00873	CcSEcCtD
Linagliptin—Back pain—Vincristine—lymphatic system cancer	0.00159	0.00868	CcSEcCtD
Linagliptin—Rash—Teniposide—lymphatic system cancer	0.00158	0.0086	CcSEcCtD
Linagliptin—Dermatitis—Teniposide—lymphatic system cancer	0.00158	0.00859	CcSEcCtD
Linagliptin—Headache—Teniposide—lymphatic system cancer	0.00157	0.00855	CcSEcCtD
Linagliptin—Back pain—Mitoxantrone—lymphatic system cancer	0.00155	0.00845	CcSEcCtD
Linagliptin—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.00153	0.00831	CcSEcCtD
Linagliptin—Diarrhoea—Fludarabine—lymphatic system cancer	0.00151	0.0082	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00147	0.00801	CcSEcCtD
Linagliptin—Myalgia—Carmustine—lymphatic system cancer	0.00147	0.008	CcSEcCtD
Linagliptin—Myalgia—Vincristine—lymphatic system cancer	0.0014	0.00764	CcSEcCtD
Linagliptin—Cough—Mitoxantrone—lymphatic system cancer	0.0014	0.00763	CcSEcCtD
Linagliptin—Infection—Carmustine—lymphatic system cancer	0.0014	0.00762	CcSEcCtD
Linagliptin—Rash—Fludarabine—lymphatic system cancer	0.00139	0.00756	CcSEcCtD
Linagliptin—Dermatitis—Fludarabine—lymphatic system cancer	0.00139	0.00755	CcSEcCtD
Linagliptin—Headache—Fludarabine—lymphatic system cancer	0.00138	0.00751	CcSEcCtD
Linagliptin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00137	0.00744	CcSEcCtD
Linagliptin—Myalgia—Mitoxantrone—lymphatic system cancer	0.00137	0.00744	CcSEcCtD
Linagliptin—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00135	0.00732	CcSEcCtD
Linagliptin—Infection—Vincristine—lymphatic system cancer	0.00134	0.00728	CcSEcCtD
Linagliptin—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00131	0.00713	CcSEcCtD
Linagliptin—Infection—Mitoxantrone—lymphatic system cancer	0.0013	0.00709	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00128	0.00699	CcSEcCtD
Linagliptin—Urticaria—Bleomycin—lymphatic system cancer	0.00128	0.00698	CcSEcCtD
Linagliptin—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00127	0.00693	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00123	0.00667	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00122	0.00662	CcSEcCtD
Linagliptin—Constipation—Carmustine—lymphatic system cancer	0.0012	0.00656	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00119	0.0065	CcSEcCtD
Linagliptin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00119	0.00648	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00116	0.00632	CcSEcCtD
Linagliptin—Constipation—Vincristine—lymphatic system cancer	0.00115	0.00626	CcSEcCtD
Linagliptin—Pancreatitis—Methotrexate—lymphatic system cancer	0.00113	0.00613	CcSEcCtD
Linagliptin—Constipation—Mitoxantrone—lymphatic system cancer	0.00112	0.0061	CcSEcCtD
Linagliptin—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00107	0.00581	CcSEcCtD
Linagliptin—Urticaria—Mitoxantrone—lymphatic system cancer	0.00104	0.00567	CcSEcCtD
Linagliptin—Hypersensitivity—Carmustine—lymphatic system cancer	0.00104	0.00565	CcSEcCtD
Linagliptin—Infestation—Methotrexate—lymphatic system cancer	0.00102	0.00557	CcSEcCtD
Linagliptin—Infestation NOS—Methotrexate—lymphatic system cancer	0.00102	0.00557	CcSEcCtD
Linagliptin—Rash—Bleomycin—lymphatic system cancer	0.00102	0.00554	CcSEcCtD
Linagliptin—Dermatitis—Bleomycin—lymphatic system cancer	0.00102	0.00554	CcSEcCtD
Linagliptin—Hypersensitivity—Vincristine—lymphatic system cancer	0.000991	0.0054	CcSEcCtD
Linagliptin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000965	0.00526	CcSEcCtD
Linagliptin—Diarrhoea—Carmustine—lymphatic system cancer	0.000964	0.00525	CcSEcCtD
Linagliptin—Diarrhoea—Vincristine—lymphatic system cancer	0.00092	0.00501	CcSEcCtD
Linagliptin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000896	0.00488	CcSEcCtD
Linagliptin—Rash—Carmustine—lymphatic system cancer	0.000888	0.00484	CcSEcCtD
Linagliptin—Dermatitis—Carmustine—lymphatic system cancer	0.000888	0.00483	CcSEcCtD
Linagliptin—Headache—Carmustine—lymphatic system cancer	0.000883	0.00481	CcSEcCtD
Linagliptin—Rash—Vincristine—lymphatic system cancer	0.000848	0.00462	CcSEcCtD
Linagliptin—Dermatitis—Vincristine—lymphatic system cancer	0.000847	0.00461	CcSEcCtD
Linagliptin—Headache—Vincristine—lymphatic system cancer	0.000843	0.00459	CcSEcCtD
Linagliptin—Immune system disorder—Methotrexate—lymphatic system cancer	0.00083	0.00452	CcSEcCtD
Linagliptin—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000828	0.00451	CcSEcCtD
Linagliptin—Rash—Mitoxantrone—lymphatic system cancer	0.000826	0.0045	CcSEcCtD
Linagliptin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000825	0.00449	CcSEcCtD
Linagliptin—Headache—Mitoxantrone—lymphatic system cancer	0.000821	0.00447	CcSEcCtD
Linagliptin—Malnutrition—Methotrexate—lymphatic system cancer	0.0008	0.00435	CcSEcCtD
Linagliptin—Back pain—Methotrexate—lymphatic system cancer	0.000773	0.00421	CcSEcCtD
Linagliptin—Cough—Methotrexate—lymphatic system cancer	0.000698	0.0038	CcSEcCtD
Linagliptin—Arthralgia—Methotrexate—lymphatic system cancer	0.000681	0.00371	CcSEcCtD
Linagliptin—Myalgia—Methotrexate—lymphatic system cancer	0.000681	0.00371	CcSEcCtD
Linagliptin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000676	0.00368	CcSEcCtD
Linagliptin—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000653	0.00355	CcSEcCtD
Linagliptin—Infection—Methotrexate—lymphatic system cancer	0.000648	0.00353	CcSEcCtD
Linagliptin—Skin disorder—Methotrexate—lymphatic system cancer	0.000634	0.00345	CcSEcCtD
Linagliptin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000595	0.00324	CcSEcCtD
Linagliptin—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000563	0.00307	CcSEcCtD
Linagliptin—Urticaria—Methotrexate—lymphatic system cancer	0.000518	0.00282	CcSEcCtD
Linagliptin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000481	0.00262	CcSEcCtD
Linagliptin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000447	0.00243	CcSEcCtD
Linagliptin—Rash—Methotrexate—lymphatic system cancer	0.000411	0.00224	CcSEcCtD
Linagliptin—Dermatitis—Methotrexate—lymphatic system cancer	0.000411	0.00224	CcSEcCtD
Linagliptin—Headache—Methotrexate—lymphatic system cancer	0.000409	0.00223	CcSEcCtD
